Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02966301
Other study ID # GMED16-001
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date December 2016
Est. completion date June 2020

Study information

Verified date July 2020
Source Medsenic
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to evaluate the early chronic GvHD events (first line therapy), if the addition of arsenic trioxide to standard therapy with corticosteroids, with or without cyclosporine, will be effective in controlling chronic GvHD and to reduce the duration of corticosteroid therapy


Description:

Graft-versus-host disease (GvHD) is the most common long-term complication in patients who underwent allogeneic transplantation. First-line therapy for chronic GVHD is based on immunosuppressive agents (corticosteroids with or without cyclosporine) achieving satisfactory response in around 30% of patients. This is a prospective, national, multicenter, non-randomized Phase II study that will include a total number of 24 patients in which, trioxide d'arsenic will be administrated at 0,15mg/kg/day. Clinical response will be evaluated based on the Working Group Report 2015, published by the National Institute of Health Consensus. Follow-up visits will be weekly for four weeks (ATO cycle), every two weeks from second to third month of ATO treatment, every month from the fourth to sixth month of ATO treatment and every 3 months, at 9 months and 12 months (final visit).


Recruitment information / eligibility

Status Completed
Enrollment 21
Est. completion date June 2020
Est. primary completion date June 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adult patients (=18 years) who have received a first allogeneic stem cell transplantation for a hematological disease (any source of hematopoietic stem cells is authorized; any category of conditioning regimen prior to allo-SCT is authorized; any type of stem cell donors is authorized) - Confirmed diagnosis of a first episode of chronic GvHD requiring systemic immunosuppressive therapy (any prior GvHD prophylaxis previously used is accepted). Chronic GvHD diagnosis is defined according to the NIH Working Group Consensus. Chronic GvHD diagnosis will be based on the evaluation of the severity of the different clinical manifestations including: - Performance status evaluation - Cutaneous evaluation measured by the percentage of extension or the presence of sclerotic features. If relevant, confirmation with a biopsy should be performed whenever possible - Oral symptoms - Ocular symptoms - Gastro-intestinal symptoms - Evaluation of liver involvement (total bilirubin, transaminases and alkaline phosphatases) - Pulmonary function evaluation - Evaluation of the musculoskeletal manifestations, especially the amplitude of the relevant articulations - Genital tract symptoms - Signed informed consent - Absence of contra-indications to the use of ATO - Subjects affiliated with an appropriate social security system - Men must use a medically acceptable method of contraception throughout the treatment period and for at least 4 months and 10 days following the last treatment administration - Women who are of childbearing potential must have a negative serum pregnancy test and agree to use a medically acceptable method of contraception throughout the study and for 3 months following the end of the study - Patient not participating or not having participated in a clinical study in the 30 days prior to his/her inclusion in the study Exclusion Criteria: - Patient developing acute GvHD (whether early or "late onset" form) - Patients developing overlap GvHD as defined by the 2014 NIH Working Group Consensus (presence of one or more acute GvHD manifestations in a patient with a diagnosis of chronic GvHD) - A "mild" form of chronic GvHD not requiring systemic immunosuppressive therapy - A "moderate" form of chronic GvHD limited to one organ site not requiring systemic immunosuppressive therapy - Patient receiving mycophenolate mofetil - Not the first episode of chronic GvHD needing systemic immunosuppressive therapy - Second allogeneic stem cell transplant - Severe cardiac diseases (congestive heart failure (NYHA class III), recent myocardial infarction (in the past 6 months before the inclusion), histories of unexplained syncope, ...) - Significant arrhythmias, electrocardiogram (EKG) abnormalities: - Congenital QT syndromes - History or presence of significant ventricular or atrial tachyarrhythmia - Clinically significant resting bradycardia (< 50 beats per minutes) - QTc>450msecformenand>470msecfor women on screening EKG (using the QTcF formula) - Right bundle branch block plus left anterior hemiblock, bifascicular block - Central or peripheral neuropathy - Neutrophils < 0.5 × 109/L - Platelets < 50 × 109/L - Potassium = 4 mEq/l* - Magnesium = 1.8 mg/dl* - Calcium = 2.15 mmol/l* - Hepatic impairment due to a suspected or proven liver damage, other than direct hepatic cGvHD involvement - PT < 50% - Renal impairment (creatinine = 100 µmol/l) - Uncontrolled systemic infection which in the opinion of the investigator is associated with an increased risk of the patients' death within 1 month after the start of therapy - Severe neurological or psychiatric disorders - Denied informed consent - Pregnancy - Women breastfeeding at selection and throughout the treatment period - If abnormal at selection, to be corrected and re-validated following electrolytes infusion, before inclusion and each drug perfusion.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Arsenic Trioxide Injectable Solution
Each patient will receive eleven perfusions of arsenic trioxide (0,15 mg/kg/Day - IV administration) over a 4 weeks period (one cycle). Patients in partial response after the 1st cycle of ATO will be eligible to receive a second cycle of ATO as consolidation therapy. A delay of 8 weeks (from the first infusion of ATO) will be observed between the two cycles of ATO therapy. The study duration will be 2 years (12 months recruitment + 12 months follow-up).

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Medsenic

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Complete or Partial Remission of Chronic Graft Versus Host Disease After a First Line Treatment With Arsenic Trioxide Clinical response will be evaluated based on the Working Group Report 2015, published by the National Institute of Health Consensus.
Response definition is as follows:
Complete remission (CR) is defined as complete disappearance of any sign of chronic GvHD.
Partial remission (PR) is defined as a significant improvement as defined by the organ or site specific measurement scale without progression in any other organ or site.
six months
Secondary Average Dose of Corticosteroids Average dose in mg/kg/day of prednisone or prednisone equivalent Average dose of Prednisone at 6 months after the first infusion of ATO
Secondary Failure Free Survival Treatment failure were defined by:
Initiation of a new systemic treatment for chronic GvHD;
Recurrent or progressive malignancy;
Death
6 months after first ATO infusion
Secondary Number of Adverse Events Tolerability and safety of ATO in combination with Prednisone, with or without Ciclosporine, in patients with chronic GvHD after allo-SCT.
Adverse events follow-up for all patients throughout the study
12 months after the first infusion of ATO for each patient
Secondary Cumulative Incidence for Non-relapse Mortality (NRM) Non-Relapse Mortality (NRM) of infectious and non-infectious origin 12 months after first ATO infusion
See also
  Status Clinical Trial Phase
Recruiting NCT03663933 - Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation Phase 2
Completed NCT03563066 - Effect of Benralizumab in Atopic Dermatitis Phase 2
Recruiting NCT04339777 - Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity Phase 2
Not yet recruiting NCT05969821 - Clonal Hematopoiesis of Immunological Significance
Completed NCT02916888 - A Study Comparing the Quality of Life of Patients in the Treatment of Eczema by Pediatric Generalists and Specialists N/A
Completed NCT02527187 - Determination of the Sensitivity and Specificity of Prick Test Betula Verrucosa Phase 2
Completed NCT01441076 - Anakinra for Behcet s Disease Phase 1/Phase 2
Completed NCT01472263 - Use of Pentoxifylline in Human T-lymphotropic Virus Type-1 (HTLV-1) Diseases Phase 3
Completed NCT03720470 - Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy Phase 3
Suspended NCT04642066 - Cold Water Immersion and Atherosclerosis, Inflammation, Fat Accumulation and Lipid Profile Parameters N/A
Completed NCT02294552 - Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT Phase 2
Completed NCT01727973 - Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy Phase 1/Phase 2
Completed NCT04103099 - Impact of HLNatural Immune Supplement on Colds N/A
Recruiting NCT03344094 - Mechanism of Action of Ocrelizumab in Multiple Sclerosis N/A
Active, not recruiting NCT05445284 - Group Education Trial to Improve Transition for Parents of Adolescents With T1D N/A
Recruiting NCT06104111 - Epigenetic Memory of Vitamin D Supplementation Phase 1
Not yet recruiting NCT05616117 - Next-generation Effects of Vitamin D Supplementation in Pregnancy
Completed NCT01490177 - Single Center Food Allergy Oral Immunotherapy Study Phase 1
Completed NCT01510626 - Omalizumab With Oral Food Immunotherapy With Food Allergies Open Label Safety Study in a Single Center Phase 1
Completed NCT03922087 - No-worry Baby Project